Medivation Aims For 2010 Approval Of Alzheimer’s Drug Dimebon

The neuroprotectant's novel mechanism of action makes it a good candidate for Alzheimer's disease drug cocktails, CEO Hung says.

More from Archive

More from Pink Sheet